Locally advanced head and neck squamous cell cancer: Treatment choice based on risk factors and optimizing drug prescription

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Brana, I ^a   Siu, L L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Chemoradiotherapy; Head and neck cancer; Human papillomavirus; Induction chemotherapy; Locally advanced; Risk stratification

Indexed keywords

AFATINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; LAPATINIB; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PLACEBO;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INDUCTION CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; ORGAN PRESERVATION; OROPHARYNX CANCER; PRESCRIPTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; WART VIRUS;

ALPHAPAPILLOMAVIRUS; CHEMORADIOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; EUROPE; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; NEOPLASMS, SQUAMOUS CELL; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; RISK FACTORS; SMOKING; TREATMENT OUTCOME;

EID: 84866768756     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds322     Document Type: Article

References (65)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr, accessed 12 February 2012.
4. Barnes L. Pathology and genetics of head and neck tumours Geneva, Switzerland: World Health Organization 2005.
5. Datema FR, Ferrier MB, van der Schroeff MP et al. Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck 2010; 32: 728-736.
6. Stenson KM, Kunnavakkam R, Cohen EEW et al. Chemoradiation for patients with advanced oral cavity cancer. The Laryngoscope 2010; 120: 93-99.
7. Turner SL, Slevin NJ, Gupta NK et al. Radical external beam radiotherapy for 333 squamous carcinomas of the oral cavity-evaluation of late morbidity and a watch policy for the clinically negative neck. Radiother Oncol 1996; 41: 21-29.
8. Carvalho AL, Nishimoto IN, Califano JA et al. Trends in incidence and prognosis for head and neck cancer in the United States: A site-specific analysis of the SEER database. Int J Cancer 2005; 114: 806-816.
9. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
10. Pignon J-P, Maître Al, Maillard E et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
11. Bernier J, Cooper JS, Pajak TF et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005; 27: 843-850.
12. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952.
13. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944. +2019.
14. Kies M, Harris J, Rotman M et al. Phase II randomized trial of postoperative chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234). Int J Radiat Oncol Biol Phys 2009; 75: S14-S15.
15. Pignon JP, Bourhis J, Domenge C et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000; 355: 949-955.
16. Furness S, Glenny AM, Worthington HV et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst Rev 2010; CD006386.
17. Blanchard P, Baujat B, Holostenco V et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 2011; 100: 33-40.
18. Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704.
19. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715.
20. Hitt R, Grau JJ, Lopez-Pousa A et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). ASCO Meeting Abstracts 2009; 27: 6009.
21. Lefebvre J, Pointreau Y, Rolland F et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): results of the randomized phase II TREMPLIN study. ASCO Meeting Abstracts 2011; 29: 5501.
22. Paccagnella A, Ghi MG, Loreggian L et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010; 21: 1515-1522.
23. Paccagnella A, Ghi MG, Floriani I et al. Concomitant chemoradiation or RT/ cetuximab versus induction TPF followed by chemoradiation or RT/cetuximab in locally advanced head and neck squamous cell carcinoma: A randomized phase III factorial study. ASCO Meeting Abstracts 2011; 29: TPS196.
24. NCCN Clinical Practice Guidelines in Oncology. Head and Neck. In NCCN Guidelines, Version 2.2011 Edition 2011.
25. Gregoire V, Lefebvre JL, Licitra L et al. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v184-v186.
26. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
27. Ang KK, Zhang QE, Rosenthal DI et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). ASCO Meeting Abstracts 2011; 29: 5500.
28. Ho C. Cetuximab in locally advanced head-and-neck cancer: defining the population. Curr Oncol 2010; 17: 48-51.
29. Gillison ML, Koch WM, Capone RB et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720.
30. Mork J, Lie AK, Glattre E et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344: 1125-1131.
31. Schwartz SM, Daling JR, Doody DR et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 1998; 90: 1626-1636.
32. D'Souza G, Kreimer AR, Viscidi R et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956.
33. Gillison ML, D'Souza G, Westra W et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420.
34. Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
35. Posner MR, Lorch JH, Goloubeva O et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011; 22: 1071-1077.
36. Ang K, Zhang Q, Wheeler RH et al. A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): impact of radiation and cisplatin intensity on outcome. ASCO Meeting Abstracts 2010; 28: 5507.
37. Rischin D, Young RJ, Fisher R et al. Prognostic significance of p16 INK4Aand human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142-4148.
38. Lassen P, Eriksen JG, Hamilton-Dutoit S et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1992-1998.
39. Lassen P, Eriksen JG, Krogdahl A et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol 2011; 100: 49-55.
40. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
41. Licitra L, Zigon G, Gatta G et al. Human papillomavirus in HNSCC: a European epidemiologic perspective. Hematol/Oncol Clin North Am 2008; 22: 1143-1153.
42. Näsman A, Attner P, Hammarstedt L et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viralinduced carcinoma? Int J Cancer 2009; 125: 362-366.
43. Blomberg M, Nielsen A, Munk C et al. Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer 2011; 129: 733-741.
44. Heath S, Willis V, Allan K et al. Clinically significant human papilloma virus in squamous cell carcinoma of the head and neck in UK practice. Clin Oncol (R Coll Radiol) 2012; 24: e18-e23.
45. Hammarstedt L, Lindquist D, Dahlstrand H et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006; 119: 2620-2623.
46. Attner P, Du J, Näsman A et al. The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer 2010; 126: 2879-2884.
47. Conway DI, Stockton DL, Warnakulasuriya KA et al. Incidence of oral and oropharyngeal cancer in United Kingdom (1990-1999)-recent trends and regional variation. Oral Oncol 2006; 42: 586-592.
48. Ligier K, Belot A, Launoy G et al. Descriptive epidemiology of upper aerodigestive tract cancers in France: incidence over 1980-2005 and projection to 2010. Oral Oncol 2011; 47: 302-307.
49. de Souza DL, Perez MM, Curado MP. Gender differences in the incidence of laryngeal and hypopharyngeal cancers in Spain. Cancer Epidemiol 2011; 35: 328-333.
50. Zigon G, Berrino F, Gatta G et al. Prognoses for head and neck cancers in Europe diagnosed in 1995-1999: a population-based study. Ann Oncol 2011; 22: 165-174.
51. Sant M, Aareleid T, Berrino F et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary. Ann Oncol 2003; 14(Suppl 5): v61-v118.
52. Berrino F, Gatta G. Variation in survival of patients with head and neck cancer in Europe by the site of origin of the tumours. EUROCARE working group. Eur J Cancer 1998; 34: 2154-2161.
53. Machtay M, Moughan J, Trotti A et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008; 26: 3582-3589.
54. Young RJ, Rischin D, Fisher R et al. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2011; 20: 1230-1237.
55. Perrone F, Suardi S, Pastore E et al. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 2006; 12: 6643-6651.
56. Sok JC, Coppelli FM, Thomas SM et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12: 5064-5073.
57. Jura N, Endres NF, Engel K et al. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009; 137: 1293-1307.
58. Soltoff SP, Carraway KL, 3rd, Prigent SA et al. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994; 14: 3550-3558.
59. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 30-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 1994; 13: 2831-2841.
60. Takikita M, Xie R, Chung JY et al. Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. J Transl Med 2011; 9: 126.
61. Wilson TR, Lee DY, Berry L et al. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 2011; 20: 158-172.
62. Wheeler DL, Huang S, Kruser TJ et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008; 27: 3944-3956.
63. Jameson MJ, Beckler AD, Taniguchi LE et al. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. Mol Cancer Ther 2011; 10: 2124-2134.
64. Chau NG, Perez-Ordonez B, Zhang K et al. Retrospective correlative study between EGFRvIII, HPV, p16, c-MET and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). In AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Nov 15-19, 2009, Boston, MA, 2009; 1.
65. Lefebvre J, Pointreau Y, Rolland F et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study. ASCO Meeting Abstracts 2009; 27: 6010.